Quick Answer
Eledon Pharmaceuticals, Inc. reported R&D Expense of $66.27 million for fiscal year 2025.
Eledon Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $66.27M | +27.5% |
| 2024 | $51.96M | +71.4% |
| 2023 | $30.31M | +11.9% |
| 2022 | $27.08M | +14.1% |
| 2021 | $23.73M | +287.1% |
| 2020 | $6.13M | -24.6% |
| 2019 | $8.13M | +19.2% |
| 2018 | $6.82M | +237.1% |
| 2017 | $2.02M | -36.6% |
| 2016 | $3.19M | -90.2% |
| 2015 | $32.64M | +123.9% |
| 2014 | $14.58M | +19.5% |
| 2013 | $12.20M | +65.5% |
| 2012 | $7.37M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.97M | -9.4% | -26.2% |
| June 30, 2025 | $20.28M | +100.6% | +49.8% |
| March 31, 2025 | $13.53M | +82.6% | -18.1% |
| September 30, 2024 | $16.52M | +108.3% | +63.5% |
| June 30, 2024 | $10.11M | +40.3% | +36.4% |
| March 31, 2024 | $7.41M | -8.7% | -6.6% |
| September 30, 2023 | $7.93M | +6.4% | +10.1% |
| June 30, 2023 | $7.20M | +25.4% | -11.2% |
- Eledon Pharmaceuticals, Inc. showed an increase of +27.5% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Eledon Pharmaceuticals, Inc.’s r&d expense has grown by 799.1% (from $7.37 million to $66.27 million).
- The most recent figure is from Eledon Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: